Advertisement

Der Orthopäde

, Volume 47, Issue 12, pp 1032–1035 | Cite as

Zoledronic acid

Treatment option for Gorham-Stout disease
  • Ozge Gulsum IlleezEmail author
  • Korhan Ozkan
  • Feyza Unlu Ozkan
  • Ali Burak Bostan
  • Fuat Akpinar
  • Bilge Bilgic
  • Ilknur Aktas
Kasuistik

Abstract

Gorham-Stout disease is a rare bone resorption disease, the etiology and prognosis of which is uncertain but it is thought to be benign. It can involve one or more bones and can cause pain, swelling, deformity and fractures in affected bones. Diagnosis is made with a combination of clinical, radiological and histopathological examinations once other causes of osteolysis have been excluded. Due to its rarity, there is no standard therapeutic approach.

Keywords

Bone Fractures Osteolysis Pain Case report 

Abbreviations

ALP

Alkaline phosphatase

AP

Anteroposterior

CT

Computed tomography

GSD

Gorham-Stout disease

MM

Multiple myeloma

PET-CT

Positron emission tomography-CT

PTH

Parathyroid hormone

VEGF

Vascular endothelial growth factor

ZA

Zoledronic acid

Zoledronsäure

Behandlungsoption für das Gorham-Stout-Syndrom

Zusammenfassung

Das Gorham-Stout-Syndrom ist eine seltene Erkrankung, bei der es zu einem Knochenabbau kommt. Ätiologie und Prognose sind ungewiss, aber es gilt als benigne. Es kann ein oder mehrere Knochen betreffen, dabei kann es zu Schmerzen, Schwellungen, Deformitäten und Frakturen in den betroffenen Knochen kommen. Die Diagnose wird anhand einer Kombination aus klinischen, radiologischen und histopathologischen Untersuchungen gestellt, sofern andere Ursachen für die Osteolyse ausgeschlossen wurden. Aufgrund seiner Seltenheit gibt es keine Standardtherapie für diese Erkrankung.

Schlüsselwörter

Knochen Frakturen Osteolyse Schmerzen Fallbericht 

Notes

Compliance with ethical guidelines

Conflict of interest

O.G. Illeez, K. Ozkan, F.U. Ozkan, A.B. Bostan, F. Akpinar, B. Bilgic and I. Aktas declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors. For images or other information within the manuscript which identify patients, consent was obtained from them and/or their legal guardians.

References

  1. 1.
    Heritier S, Donadieu J (2012) Gorham’s disease and intra-osseous vascular abnormalities. Bull Cancer 99(5):599–604Google Scholar
  2. 2.
    Gorham LW, Stout AP (1955) Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am 37(5):985–1004CrossRefGoogle Scholar
  3. 3.
    Tolis K, Triantafyllopoulos IK, Tournis S, Papaioannou NA (2016) Gorham-Stout disease of the pelvis: Seven years follow up with complete radiological evaluation. J Musculoskelet Neuronal Interact 16(1):79–82Google Scholar
  4. 4.
    Sahoo RK, Jagannathan B, Palanichamy G, Natarajan V (2012) Anaesthetic consideration in patients with Gorham’s syndrome: a case report and review of the literature. Indian J Anaesth 56(4):391–393CrossRefGoogle Scholar
  5. 5.
    Yoo SY, Hong SH, Chung HW, Choi JA, Kim CJ, Kang HS (2002) MRI of Gorham’s disease: findings in two cases. Skeletal Radiol 31(5):301–306CrossRefGoogle Scholar
  6. 6.
    Mawk JR, Obukhov SK, Nichols WD, Wynne TD, Odell JM, Urman SM (1997) Successful conservative management of Gorham disease of the skull base and cervical spine. Childs Nerv Syst 13(11–12):622–625CrossRefGoogle Scholar
  7. 7.
    Patel DV (2005) Gorham’s disease or massive osteolysis. Clin Med Res 3:65–74CrossRefGoogle Scholar
  8. 8.
    Angelini A, Mavrogenis AF, Rimondi E, Rossi G, Ruggieri P (2017) Current concepts for the diagnosis and management of eosinophilic granuloma of bone. J Orthop Traumatol 18:83–90CrossRefGoogle Scholar
  9. 9.
    Mollee P (2009) Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 30(3):93–103Google Scholar
  10. 10.
    Nikolaou VS, Chytas D, Korres D, Efstathopoulos N (2014) Vanishing bone disease (Gorham-Stout syndrome): a review of a rare entity. World J Orthop 5(5):694–698CrossRefGoogle Scholar
  11. 11.
    Yerganyan VV, Body JJ, De Saint Aubain N, Gebhart M (2015) Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid. J Bone Oncol 4(2):42–46CrossRefGoogle Scholar
  12. 12.
    Lehmann G, Pfeil A, Bottcher J et al (2009) Benefit of a 17-year long-term bisphosphonate therapy in a patient with GorhamStout syndrome. Arch Orthop Trauma Surg 129:967–972CrossRefGoogle Scholar
  13. 13.
    Hammer F, Kenn W, Wesselmann U et al (2005) Gorham-Stout disease—stabilization during bisphosphonate treatment. J Bone Miner Res 20:350–353CrossRefGoogle Scholar
  14. 14.
    Stefanidou M, Ioannidou D, Panayotides J et al (2004) Cutaneous vascular malformation associated with osteolysis or Gorham’s sign. Int J Dermatol 43:958–961CrossRefGoogle Scholar
  15. 15.
    Avelar RL, Martins VB, Antunes AA, de Oliveira Neto PJ, Andrade ES (2010) Use of zoledronic acid in the treatment of Gorham’s disease. Int J Pediatr Otorhinolaryngol 74(3):319–322CrossRefGoogle Scholar
  16. 16.
    Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R (2005) Treatment of Gorham’s disease with zoledronic acid. Oral Oncol 41:747–750CrossRefGoogle Scholar
  17. 17.
    Kuriyama DK, McElligott SC, Glaser DW, Thompson KS (2010) Treatment of Gorham-Stout disease with zoledronic acid and interferon-α: a case report and literature review. J Pediatr Hematol Oncol 32(8):579–584CrossRefGoogle Scholar
  18. 18.
    Cramer SL, Wei S, Merrow AC, Pressey JG (2016) Gorham-stout disease successfully treated with Sirolimus and Zoledronic acid therapy. J Pediatr Hematol Oncol 38(3):e129–e132CrossRefGoogle Scholar
  19. 19.
    Ocarino NM, Serakides R (2006) Effect of the physical activity on normal bone and on the osteoporosis prevention and treatment. Rev Bras Med Esporte 12(3):149–152CrossRefGoogle Scholar
  20. 20.
    Ellati R, Attili A, Haddad H, Al-Hussaini M, Shehadeh A (2016) Novel approach of treating Gorham-Stout disease in the humerus—Case report and review of literature. Eur Rev Med Pharmacol Sci 20(3):426–432Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Ozge Gulsum Illeez
    • 1
    Email author
  • Korhan Ozkan
    • 2
  • Feyza Unlu Ozkan
    • 1
  • Ali Burak Bostan
    • 2
  • Fuat Akpinar
    • 2
  • Bilge Bilgic
    • 3
  • Ilknur Aktas
    • 1
  1. 1.Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and RehabilitationUniversity of Health SciencesIstanbulTurkey
  2. 2.Faculty of Medicine, Göztepe Training and Research Hospital, Department of Orthopaedics and TraumatologyIstanbul Medeniyet UniversityIstanbulTurkey
  3. 3.Istanbul Faculty of Medicine, Department of PathologyIstanbul UniversityIstanbulTurkey

Personalised recommendations